VYNE Therapeutics Inc.
8-K
March 11, 2026
Key Highlights
- Nasdaq granted VYNE Therapeutics an extension until September 7, 2024, to regain...
- A Nasdaq listing is crucial for VYNE's ability to raise money, maintain public p...
- The company is actively evaluating all options, including a reverse stock split,...
Read Analysis
🤖 AI Generated